1: For newborns of HBsAg-positive mothers, HBIG should be administered as early as possible within 24 h after birth (preferably 12 h after birth) at a dose of ≥100 IU, along with 10 μg recombinant yeast hepatitis B vaccine at different sites, and the second and third doses of hepatitis B vaccine at 1 and 6 months of age, respectively, to significantly improve the effectiveness of interruption of mother-to-child transmission. 2: Newborns can receive breastfeeding from HBsAg-positive mothers after HBIG and hepatitis B vaccine within 12 h of birth 3: High serum HBV DNA load in pregnant patients is one of the high-risk factors for mother-to-child transmission, and standard hepatitis B immunoprophylaxis in newborns and effective antiviral therapy in mothers can significantly reduce the incidence of mother-to-child transmission of HBV. If the HBV DNA load is greater than 2×106 IU/ml detected in mid- to late pregnancy, tenofovir (TDF), telbivudine (LDT) or lamivudine (LAM) can be given starting from the 24th to 28th week of gestation after full communication with the patient and weighing the pros and cons. It is recommended that the drug be discontinued 1 to 3 months after delivery, and breastfeeding is possible after discontinuation.